- Home
- EOD vs ACIU Comparison
EOD vs ACIU Comparison
Compare EOD & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOD
- ACIU
- Stock Information
- Founded
- EOD 2007
- ACIU 2003
- Country
- EOD United States
- ACIU Switzerland
- Employees
- EOD N/A
- ACIU N/A
- Industry
- EOD Investment Managers
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- EOD Finance
- ACIU Health Care
- Exchange
- EOD Nasdaq
- ACIU Nasdaq
- Market Cap
- EOD 245.0M
- ACIU 213.3M
- IPO Year
- EOD N/A
- ACIU 2016
- Fundamental
- Price
- EOD $5.62
- ACIU $2.46
- Analyst Decision
- EOD
- ACIU Strong Buy
- Analyst Count
- EOD 0
- ACIU 2
- Target Price
- EOD N/A
- ACIU $10.00
- AVG Volume (30 Days)
- EOD 118.1K
- ACIU 136.3K
- Earning Date
- EOD 01-01-0001
- ACIU 11-04-2025
- Dividend Yield
- EOD 9.28%
- ACIU N/A
- EPS Growth
- EOD N/A
- ACIU N/A
- EPS
- EOD N/A
- ACIU N/A
- Revenue
- EOD N/A
- ACIU $36,362,036.00
- Revenue This Year
- EOD N/A
- ACIU N/A
- Revenue Next Year
- EOD N/A
- ACIU $1,022.98
- P/E Ratio
- EOD N/A
- ACIU N/A
- Revenue Growth
- EOD N/A
- ACIU 86.71
- 52 Week Low
- EOD $3.73
- ACIU $1.43
- 52 Week High
- EOD $4.71
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- EOD 43.87
- ACIU 60.92
- Support Level
- EOD $5.65
- ACIU $2.12
- Resistance Level
- EOD $5.71
- ACIU $2.35
- Average True Range (ATR)
- EOD 0.05
- ACIU 0.14
- MACD
- EOD -0.02
- ACIU 0.04
- Stochastic Oscillator
- EOD 5.26
- ACIU 76.79
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.